key: cord-0723762-la3zyvnq authors: Rodríguez Rodríguez, Mario; Castro Quismondo, Nerea; Zafra Torres, Denis; Gil Alos, Daniel; Ayala, Rosa; Martinez‐Lopez, Joaquín title: Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid‐19 patients date: 2021-01-27 journal: Int J Lab Hematol DOI: 10.1111/ijlh.13476 sha: 029a6ef0fa909e80861b423231bd22c226c089d6 doc_id: 723762 cord_uid: la3zyvnq nan ulopathy characterized by a marked increase in D-dimer, but with a low incidence of both thrombocytopenia and hypofibrinogenaemia. Also, a tendency to develop thrombosis has been described. 1, 2 These features are different from the coagulopathy observed in other infections and from common disseminated intravascular coagulation (DIC). 3 A considerably marked increase in inflammation markers has been observed in patients with COVID-19 disease, [4] [5] [6] and this pro-inflammatory state can cause endothelial dysfunction, an increase in tissue factor and von Willebrand factor (VWF) release and an activation of the coagulation cascade, leading altogether to a prothrombotic situation. A disintegrin and metalloprotease with thrombospondin motif 13 (ADAMTS13) regulates the size of VWF multimers and is known to be a marker of endothelium dysfunction in sepsis, and changes in ADAMTS13 and VWF have been reported in the context of an endothelial activation. [7] [8] [9] Furthermore, ultrastructural features of endothelial cell destruction and SARS-CoV-2 visible within the cell have been described in patients who died from COVID-19. 10 We aimed to assess the possible involvement of ADAMTS13 in the coagulopathy associated with COVID-19 and its relevance in the severity and prognosis of the infection. We carried out a retrospective study in 100 consecutive PCR- percentage. Normality distribution was tested in our data; the Mann-Whitney test was used to analyse differences in continuous variables. Spearman's r was used to explore the relationship between ADAMTS13 and VWF, D-dimer, ferritin and LDH. Fisher's exact was used to explore the association between ADAMTS13 activity below median value and increased D-dimer plasma concentration. The Kaplan-Meier analysis was performed to assess whether ADAMTS13 activity can predict mortality, and patients were tracked for 60 days. Univariate and multivariate analyses were performed to assess the influence of laboratory values on the risk of death. Statistical significance was set at P values <.05. Statistical analyses were performed using ibm spss 23.0 (IBM Inc). A total of 100 hospitalized patients with confirmed COVID-19 were included in the study. Of the 100 patients, 50 were considered as severe COVID-19 disease cases and 50 as nonsevere form of COVID-19 disease. Median age was 60.5 years. Regarding age, there were no significant differences between both groups, and 55% of patients were older than 60 years. There were 70% males and 30% females. 4 cases developed venous thromboembolism during admission and 1 case presented an arterial thrombotic event, all of them within the severe disease group. All patients received low molecular weight heparin (LMWH) as thromboprophylaxis. Overall, there were 19 deaths (19%), all of them in the severe disease group. Analytical data of the whole sample and of both groups are shown in Table 1 . D-dimer, ferritin and lactate dehydrogenase were significantly increased in the severe COVID-19 disease cases. Severe cases had significantly lower ADAMTS13 activity and higher plasma concentration of VWF (Table 2 ). ADAMTS13 activity was negatively cor- The 19 nonsurvivors had significantly lower ADAMTS13 activity and higher plasma concentration of VWF (Table 2 ). 15 out of 19 nonsurvivors had ADAMTS13 activity lower than 61%. Cases with ADAMTS13 activity lower than 61% showed a significant association with in-hospital death (P = .011). The Kaplan-Meier analysis confirmed a significantly lower survival in those cases with ADAMTS13 levels below 61% (Figure 1) In conclusion, the strong inflammation and the endothelial dysfunction caused by the SARS-CoV-2 infection might play a fundamental role in the coagulopathy, the levels of VWF and ADAMTS13 activity, the severity of the disease and the increased thrombotic risk. These data are consistent with previous findings [11] [12] [13] [14] [15] [16] [17] [18] and might suggest that ADAMTS13 activity could be a prognosis marker in COVID-19 patients. ADAMTS13, coagulopathy, COVID-19, prognosis, von Willebrand factor The authors declare no competing interests. The data that support the findings of this study are available from the corresponding author upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Incidence of venous thromboembolism in hospitalized patients with COVID-19 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia COVID-19 coagulopathy: an evolving story Vasculopathy and coagulopathy associated with SARS-CoV-2 infection Complex immune dysregulation in COVID-19 patients with severe respiratory failure The role of ADAMTS-13 in the coagulopathy of sepsis Variation of endothelium-related hemostatic factors during sepsis. Microcirculation Inflammation, von Willebrand factor, and ADAMTS13. Blood Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19 Los ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2 A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients A relative ADAMTS13 deficiency supports the presence of secondary microangiopathy in COVID 19 ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients The ADAMTS13-von Willebrand factor axis in COVID-19 patients Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality